Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate
Authors:
- 26 October 2009
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 31 (1) , 72-81
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialThe Lancet, 2007
- Fludarabine in chronic lymphocytic leukaemiaExpert Opinion on Pharmacotherapy, 2006
- Fludarabine in Comparison to Alkylator-based Regimen as Induction Therapy for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysisLeukemia & Lymphoma, 2004
- Oral fludarabine therapy in chronic lymphocytic leukemia - increased convenienceThe Hematology Journal, 2004
- Oral FludarabineDrugs, 2003
- Cellular and Clinical Pharmacology of FludarabineClinical Pharmacokinetics, 2002
- The bioavailability of oral fludarabine phosphate is unaffected by foodThe Hematology Journal, 2001
- Clinical Pharmacokinetics of Nucleoside AnaloguesClinical Pharmacokinetics, 2000
- Pharmacokinetic Study of Single Doses of Oral Fludarabine Phosphate in Patients With “Low-Grade” Non-Hodgkin's Lymphoma and B-Cell Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 1999
- Fludarabine: a new agent with major activity against chronic lymphocytic leukemiaBlood, 1989